Checkpoint Therapeutics Inc banner

Checkpoint Therapeutics Inc
NASDAQ:CKPT

Watchlist Manager
Checkpoint Therapeutics Inc Logo
Checkpoint Therapeutics Inc
NASDAQ:CKPT
Watchlist
Price: 4.26 USD 0.71%
Market Cap: $370.7m

Multiples-Based Value

The Multiples-Based Value of one CKPT stock under the Base Case scenario is hidden USD. Compared to the current market price of 4.26 USD, Checkpoint Therapeutics Inc is hidden .

Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

CKPT Multiples-Based Value
LOCKED
Unlock
Worst Case
Base Case
Best Case

Multiples Across Competitors

CKPT Competitors Multiples
Checkpoint Therapeutics Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Checkpoint Therapeutics Inc
NASDAQ:CKPT
356.8m USD 8 703.3 -6.3 -5.8 -5.8
FR
Pharnext SCA
OTC:PNEXF
6T USD 33 690 872.8 -160 127.7 -194 446.1 -192 227.3
US
Abbvie Inc
NYSE:ABBV
366.3B USD 6.1 89.1 14.8 20.5
US
Exact Sciences Corp
NASDAQ:EXAS
356.4B USD 6.2 -96.2 951.3 -107.4
US
Amgen Inc
NASDAQ:AMGN
190.8B USD 5.2 24.7 14.3 14.3
US
Gilead Sciences Inc
NASDAQ:GILD
171.6B USD 5.8 20.1 12.5 15.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
115.6B USD 9.7 29.3 22.1 23.1
US
Epizyme Inc
F:EPE
94.1B EUR 2 091 -533.6 -581 -565.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
79.2B USD 5.6 17.8 13.3 15.2
AU
CSL Ltd
ASX:CSL
68B AUD 3.2 35.2 11.6 14.6
US
Seagen Inc
F:SGT
39.3B EUR 20.1 -61.8 -66.6 -60.1
P/S Multiple
Revenue Growth P/S to Growth
US
Checkpoint Therapeutics Inc
NASDAQ:CKPT
Average P/S: 3 063 793.5
8 703.3
2 734%
3.2
FR
Pharnext SCA
OTC:PNEXF
33 690 872.8
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.1
9%
0.7
US
Exact Sciences Corp
NASDAQ:EXAS
6.2
12%
0.5
US
Amgen Inc
NASDAQ:AMGN
5.2
3%
1.7
US
Gilead Sciences Inc
NASDAQ:GILD
5.8
5%
1.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
9.7
11%
0.9
US
E
Epizyme Inc
F:EPE
2 091
N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.6
10%
0.6
AU
CSL Ltd
ASX:CSL
3.2
4%
0.8
US
S
Seagen Inc
F:SGT
20.1
30%
0.7
P/E Multiple
Earnings Growth PEG
US
Checkpoint Therapeutics Inc
NASDAQ:CKPT
Average P/E: 36.1
Negative Multiple: -6.3
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -160 127.7 N/A N/A
US
Abbvie Inc
NYSE:ABBV
89.1
97%
0.9
US
Exact Sciences Corp
NASDAQ:EXAS
Negative Multiple: -96.2 N/A N/A
US
Amgen Inc
NASDAQ:AMGN
24.7
20%
1.2
US
Gilead Sciences Inc
NASDAQ:GILD
20.1
16%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
29.3
17%
1.7
US
E
Epizyme Inc
F:EPE
Negative Multiple: -533.6 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.8
13%
1.4
AU
CSL Ltd
ASX:CSL
35.2
10%
3.5
US
S
Seagen Inc
F:SGT
Negative Multiple: -61.8 N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Checkpoint Therapeutics Inc
NASDAQ:CKPT
Average EV/EBITDA: 148.6
Negative Multiple: -5.8
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -194 446.1 N/A N/A
US
Abbvie Inc
NYSE:ABBV
14.8
12%
1.2
US
Exact Sciences Corp
NASDAQ:EXAS
951.3
261%
3.6
US
Amgen Inc
NASDAQ:AMGN
14.3
10%
1.4
US
Gilead Sciences Inc
NASDAQ:GILD
12.5
9%
1.4
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
22.1
16%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -581 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
13.3
18%
0.7
AU
CSL Ltd
ASX:CSL
11.6
7%
1.7
US
S
Seagen Inc
F:SGT
Negative Multiple: -66.6 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Checkpoint Therapeutics Inc
NASDAQ:CKPT
Average EV/EBIT: 17.2
Negative Multiple: -5.8
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -192 227.3 N/A N/A
US
Abbvie Inc
NYSE:ABBV
20.5
23%
0.9
US
Exact Sciences Corp
NASDAQ:EXAS
Negative Multiple: -107.4 N/A N/A
US
Amgen Inc
NASDAQ:AMGN
14.3
3%
4.8
US
Gilead Sciences Inc
NASDAQ:GILD
15.5
13%
1.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23.1
17%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -565.5 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
15.2
23%
0.7
AU
CSL Ltd
ASX:CSL
14.6
10%
1.5
US
S
Seagen Inc
F:SGT
Negative Multiple: -60.1 N/A N/A
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett